# Natera, Inc. Common Stock (NTRA)

> Natera, Inc. Common Stock (NTRA) trades at $288.48 (-9.59%) as of 5:10:52 PM EST on Nov 16, 2026, -26.68% over the past month. Market cap is $46.27B, with 4.2 days to cover in short interest.

Canonical: https://massive.com/quote/ntra
Data as of: 2026-11-16T22:10:52.893Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$288.48** -30.60 (-9.59%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$291.87** +3.39 (+1.18%)
As of 5:10:52 PM EST on Nov 16, 2026 · After hours

## Stock performance

How Natera, Inc. Common Stock (NTRA) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -9.59% |
| 1W | -9.96% |
| 1M | -26.68% |
| YTD | +25.92% |
| 1Y | +40.01% |
| 52-wk range | $181.00 – $437.41 |

From daily closes through Nov 16, 2026.

## Key statistics

Today's trading snapshot for NTRA: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $287.83 – $315.21 |
| Open | $313.99 |
| Prev close | $319.09 |
| Volume | 2.33M |
| Market cap | $46.27B |
| Shares out | 145M |

## Valuation and profitability ratios

Valuation and profitability ratios for Natera, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 15.91 |
| P/B | 24.75 |
| P/FCF | 881.88 |
| ROE | -8.8% |
| ROA | -6.0% |
| Debt/Equity | 0.04 |
| Div yield | 0.00% |

As of Nov 13, 2026

## Insider trading

[Natera, Inc. Common Stock (NTRA) insider trading](https://massive.com/quote/ntra/insider-trading.md): open-market Form 4 buys and sells by Natera, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Natera, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 5, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 5, 2026, Natera, Inc. issued a press release announcing the results for its third quarter ended September 30, 2026.”
- Jul 6, 2026 · Director departure
  “On July 1, 2026, Monica Bertagnolli notified the Board of Directors (the "Board") of Natera, Inc. ("Natera" or the "Company") of her intention to resign as a member of the Board and any committees of the Board, effective July 1, 2026, due to her new position with the National Academy of Medicine.”
- Jun 16, 2026 · Annual meeting results
  “On June 11, 2026, at the Annual Meeting, the Company's stockholders voted on five proposals... The tabulation of the stockholders' votes on each proposal brought before the Annual Meeting is as follows: Proposal 1: The election of three directors to serve as Class II directors until the 2029 annual meeting of stockholders, and the election of one director to serve as a Class I director until the 2028 annual meeting of stockholders.”
- Jun 5, 2026 · Director appointment
  “The Board of Directors (the "Board") of Natera, Inc., a Delaware corporation (the "Company") (i) increased the size of the full Board from eleven to twelve members and (ii) appointed Thomas Lynch as a member of the Board, in each case effective as of June 2, 2026. Dr. Lynch will serve as a Class I director, with an initial term expiring at the 2028 annual meeting of stockholders. The Board determined that Dr. Lynch qualifies as an independent director pursuant to the Securities Act of 1933, as amended, and the listing standards of The Nasdaq Stock Market. The Board has appointed Dr. Lynch to the Human Capital Committee of the Board.”
- Apr 1, 2026 · Executive compensation change
  “In connection with his appointment to the Board, Dr. Rubin will be entitled to receive cash and equity compensation consistent with that of the Company's other non-employee directors. The initial equity award granted to Dr. Rubin will vest as to one-third of the shares covered by such award on each of March 26, 2027, 2028, and 2029.”

## NTRA short interest

How heavily NTRA is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 4.2 |
| Short interest | 6.07M |
| Avg volume | 1.46M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## NTRA news

The latest news and headlines about Natera, Inc. Common Stock (NTRA).

- [Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook](https://www.zacks.com/stock/news/3026700/natera-q3-earnings-call-highlights-6b-target-raised-2026-outlook?cid=CS-ZC-FT-analyst_blog_plus|earnings_call_takeaways-3026700) · Zacks Investment Research · Nov 9, 2026 · positive sentiment
- [NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up](https://www.zacks.com/stock/news/3026170/ntra-q3-loss-wider-than-expected-revenues-beat-26-sales-view-up?cid=CS-ZC-FT-analyst_blog|earnings_article-3026170) · Zacks Investment Research · Nov 9, 2026 · neutral sentiment
- [Decoding Healthcare ETFs: Different Sectors, Different Strategies](https://www.fool.com/coverage/etfs/2026/11/07/decoding-healthcare-etfs-different-sectors-different-strategies/?source=iedfolrf0000001) · The Motley Fool · Nov 7, 2026 · positive sentiment
- [Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates](https://www.zacks.com/stock/news/3025043/natera-ntra-reports-q3-loss-beats-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3025043) · Zacks Investment Research · Nov 5, 2026 · negative sentiment
- [Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates](https://www.zacks.com/stock/news/3023514/caris-life-sciences-inc-cai-q3-earnings-and-revenues-top-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3023514) · Zacks Investment Research · Nov 4, 2026 · positive sentiment

## About Natera, Inc. Common Stock

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 6.14K |
| Listed | Jul 2, 2015 |

[Company website](https://www.natera.com)

## FAQ

### What is the Natera, Inc. Common Stock (NTRA) stock price today?

Natera, Inc. Common Stock (NTRA) is trading at $288.48 (-9.59% on the day) as of 5:10:52 PM EST on Nov 16, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Natera, Inc. Common Stock?

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin…

### What is the short interest in NTRA?

As of Oct 30, 2026, NTRA has 6.07M shares short and 4.2 days to cover.

### What exchange is NTRA listed on?

Natera, Inc. Common Stock (NTRA) trades on Nasdaq in USD, in the SERVICES-MEDICAL LABORATORIES industry.

## Live data

Prices here are 15-minute delayed. For real-time NTRA quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=NTRA`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Natera, Inc. Common Stock (NTRA) insider trading](https://massive.com/quote/ntra/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
